Cloudbreak Pharma FY26 H1 net loss widens 1,024.6% to US$ 47.95 million

• Cloudbreak Pharma posted a net loss of US$47.95 million, swinging from profit, as operating loss widened 43.56% to US$48.34 million.
• General and administrative costs climbed 68.64% to US$15.8 million, while R&D spending rose 34.21% to US$31.85 million.
• Cash and cash equivalents fell to US$32.75 million, while bank borrowings more than doubled to US$6 million.
• CBT-001 Phase 3 program hit a key milestone, with top-line 12-month efficacy data expected in Q3 2026.
• CBT-004 advanced toward Phase 3 after an end-of-phase 2 FDA meeting, while the FDA cleared CBT-199 and CBT-358 to proceed with clinical studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12308790), on August 31, 2026, and is solely responsible for the information contained therein.